White House targets PBM reform as drug pricing concerns escalate

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Tue, Feb 18, 2025, 4:51 PM

The Trump administration is taking steps to meet with pharmaceutical companies to examine pharmacy benefit managers (PBMs) and discuss reforms aimed at eliminating PBM "middlemen." Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the political climate surrounding PBMs, exploring how these intermediaries affect consumer choices and potential cost savings on drug prices.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written by Angel Smith